• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Bicalutamide Teva 150 mg
    / Teva


    Active Ingredient
    Bicalutamide 150 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    30 X 150 mg

    not in the basket chart 80700 2488

    Related information


    Dosage

    One tablet per day.
    See prescribing information for full details.


    Indications

    In patients with locally advanced prostate cancer (T3-T4, any N, M0; T1-T2, N+, M0), as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy.For the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.


    Contra-Indications

    Females and children. Must not be given to any patient who has shown a hypersensitivity to the active substance or any of the excipients. Co-administration of terfenadine, astemizole or cisapride is contraindicated.


    Special Precautions

    Please contact distributor for full information.


    Side Effects

    Please contact distributor for full information.


    Drug interactions

    Please contact distributor for full information.


    Manufacturer
    Teva Pharmaceutical Industries Ltd, Israel
    CLOSE